Phase 1 · NCT05916560
A Study of LY3437943 in Participants With Impaired and Normal Liver Function
A Parallel-Group, Single-Dose, Phase 1, Open-Label Study to Investigate the Pharmacokinetics of LY3437943 in Participants With Hepatic Impairment Compared With Healthy Participants
CompletedVerified
Registry record
Trial details
- Trial
- A Study of LY3437943 in Participants With Impaired and Normal Liver Function
- ClinicalTrials.gov ID
- NCT05916560
- Indication
- Healthy, Hepatic Insufficiency
- Phase
- Phase 1
- Study type
- Interventional
- Sponsor
- Eli Lilly and Company
- Enrolment
- 43
- Status
- Completed
- Interventions
- Drug: LY3437943
- Comparator
- Not reported
- Eligible ages
- 18 Years – 85 Years
- Locations
- 5 sites · United States
- Study start
- 13 Jul 2023
- Primary completion
- 2 Mar 2025
- Study completion
- 2 Mar 2025
Verification
- Last verified
- 4 Sept 2026
- Source
- ClinicalTrials.gov
- Registry last updated
- 18 Apr 2025
Endpoints
Primary
Pharmacokinetics (PK): Area under the concentration versus time curve from time zero to infinity (AUC0-∞) of LY3437943; PK: Maximum observed concentration (Cmax) of LY3437943